Breakthrough Diabetes Medication Shows Promise in Treating Fatty Liver Disease

Recent research reveals that dapagliflozin, a medication initially developed for diabetes, has demonstrated efficacy in treating a serious liver condition known as MASH (metabolic dysfunction-associated steatohepatitis), commonly referred to as fatty liver disease. Published on June 4 in The BMJ, this clinical trial uncovered that dapagliflozin significantly reduced liver fat and mitigated scarring, a principal concern with MASH. Remarkably, roughly 23% of participants on dapagliflozin experienced complete resolution of fatty liver disease, in contrast to merely 8% on a placebo. Led by an insightful physician, the research indicated that a 48-week dapagliflozin regimen resulted in considerable MASH improvement without exacerbating liver scarring. With over 5% of global adults impacted, the study, featuring 154 individuals, uniquely addressed confirmed MASH cases through liver biopsy. Notably, it emphasized the necessity for broader inclusion of Black patients in clinical trials, given their elevated risk for associated conditions and the historical lack of representation. This underscores the importance of ensuring equitable healthcare advancements for all communities.